Genentech as part of the Roche Group is at the forefront when it comes to collaboration with biotechs at all development stages to drive the application of technology and modality platforms that have the potential to transform discovery as well as generate innovative medicines beyond the standard of care.
C4T – Expanded collaboration agreement to advance research in the emerging degrader-antibody conjugate (DAC) modality. By combining antibody-drug conjugation (ADC) and targeted protein degradation (TPD) the partners seek to develop a new way to treat cancers that leverages both the specificity and catalytic efficiency of degraders with the delivery capabilities of ADCs.
Manifold Bio – Research collaboration to develop multiple next-generation brain shuttles for neurological diseases leveraging Manifold's AI-guided direct-to-vivo platform.
NVIDIA – Partnership to accelerate R&D by using AI and computing technology to better understand disease biology and develop novel therapeutics.
Orionis Biosciences – Collaboration to discover and develop novel small molecule medicines, including molecular glues, for challenging targets in major disease areas, including oncology and neurodegeneration.
Recursion – Research collaboration with Roche and Genentech to use machine learning and high content screening methods at scale to map complex biology in neuroscience and oncology.
Sangamo Therapeutics – Global epigenetic regulation and capsid delivery license agreement to develop novel genomic medicines for neurodegenerative diseases.
Vividion Therapeutics – Research collaboration to discover and develop compounds targeting novel E3 ligases and a range of oncology and immunology therapeutic targets based on Vividion’s covalent chemistry.
Connect with our partnering experts to start the conversation.